Neutralizing Antibodies and Vaccine Development Against the HIV-1 Virus

Dear Colleagues,

HIV-1 is the etiological agent of AIDS in humans. As of 2022, 39 million people are living with HIV. Despite decades of research, the development of a potent HIV-1 vaccine still remains a challenge due to factors such as evolving virus genetic diversity, immune evasion and integration into the host genome, resulting in the virus becoming resistant to host immunity and treatments. Despite these obstacles, there is still an urgent need for the development of an effective HIV-1 vaccine.

This Special Issue is intended to cover all the past and ongoing efforts in the development of an HIV-1 vaccine that uses broadly neutralizing antibodies (bnAbs) against the HIV-1 virus. This is an attempt to compile up-to-date information regarding HIV-1 vaccine development and its related challenges. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

• HIV-1 bnAbs;
• Strategies for HIV-1 bnAbs development;
• Challenges in HIV-1 vaccine development;
• HIV-1 and its complex mechanisms of immune evasion.

We invite authors to contribute a research article or review for the Special Issue “Neutralizing Antibodies and Vaccines Development against the HIV-1 Virus” in Vaccines (ISSN: 2076-393X, impact factor 7.8).

Dr. Ann Hessell
Dr. Pooja Khatkar
Dr. Qingsheng Li
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.